ClinicalTrials.gg
RecruitingNCT06855277AcTFirstUpdated Oct 15, 2026

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

A Phase 3 interventional study of AAA817 and ARPI in Prostate Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 106 sites in 12 countries. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Diagnostic

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 15, 20266 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
940
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 82 studies in Prostatic Neoplasms by Novartis — 13 open to participants now, 25 under way, 4 of them phase 3. Prostatic Neoplasms · Novartis.

Planned enrollment
2nd of 70
940 · median 72
Started
2025
with 10 others
Phase 3
12 of 82
2 open now
Primary completion
2028-09
later than 15 of 24 live
Registered
66th of 82
by date

Among the 82 studies in Prostatic Neoplasms by Novartis, this one is the 2nd largest by planned enrollment of the 70 interventional ones that give a count, is one of 11 that started in 2025, is one of 12 in phase 3, reaches primary completion later than 15 of the 24 other live ones, and was the 66th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

13 of the 82 studies in Prostatic Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Prostatic Neoplasms by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or [177Lu]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.

Read the detailed description

This is a phase III, open label, multicenter randomized study. The study aims at evaluating the superiority of 225Ac-PSMA-617 combined with androgen receptor pathway inhibitor (ARPI) over a change of ARPI or chemotherapy or [177Lu]Lu-PSMA-617 (AAA617) in prolonging progression free survival (rPFS).

Screening period: At screening, the participants will be assessed for eligibility and will undergo a positron emission tomography (PET)/computed tomography (CT) scan to evaluate PSMA positivity. Only participants with PSMA positive cancer and confirmed eligibility criteria will be randomized.

Participants randomized to the investigational arms will receive up to 6 doses of AAA817 10 Mbq +/- 10% given intravenously with or without an ARPI (oral enzalutamide or oral abiraterone) per investigator's choice. Treatment with ARPI should continue as per protocol end of treatment criteria.

Participants randomized to SoC will be treated with an ARPI change (oral enzalutamide or oral abiraterone) or taxane-based chemotherapy (docetaxel or cabazitaxel) or [177Lu]Lu-PSMA-617 (AAA617)' per investigator's choice. Treatment with ARPI should continue as per protocol end of treatment criteria. Treatment duration with taxane-based chemotherapy or AAA617will depend on the chosen regimen per the investigator's discretion following local guidelines as per standard of care and product labels and adhere to the protocol end of treatment criteria.

Supportive care will be allowed in both arms at the discretion of the investigator and includes available care for the eligible participant according to best institutional practice for mCRPC treatment, including androgen deprivation therapy (ADT).

Safety will be assessed routinely during the study. Crossover is not allowed among study arms.

The study will be conducted in the USA among other countries globally.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Positive Metastatic Castration Resistant Prostate Cancer
  • PSMA
  • PSMA-positive
  • AAA817
  • [225AC] AC-PSMA-617
  • Radioligand Therapy
  • RLT
  • Androgen receptor pathway inhibitor
  • ARPI
  • Taxane
  • Metastatic castration resistant prostate cancer
  • mCRPC
  • AcTFirst
  • [177Lu]Lu- PSMA-617
  • AAA617
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Signed must be obtained prior to participation in the study.
  • Participants must be adults ≥ 18 years of age.
  • Participants must have an performance status of 0 to 2.
  • Participants must have histological, and/or cytological confirmation of adenocarcinoma of the prostate. Participants with mixed histology (neuroendocrine) are not eligible.
  • Participants who have received taxane-based chemotherapy in mHSPC setting are eligible if they are deemed appropriate for chemotherapy, ARPI change or AAA617 as the next in the opinion of the Investigator. Note: Participants who have received taxane-based chemotherapy for mCRPC are excluded.
  • Participants must not have received taxane-based chemotherapy in mCRPC setting (allowed in mHSPC setting).
  • Participants must have PSMA-PET positive disease using a PSMA imaging agent that is approved as per protocol.
  • Participant must have been diagnosed with mCRPC with documented progressive disease while on treatment with ARPI in mHSPC or earlier setting as their last treatment (and did not progress on more than one ARPI).

    • Participants with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated castration-resistant prostate cancer, as per local testing, may be enrolled if they had prior exposure to PARPi.

Key Exclusion Criteria:

  • Previous anti-cancer treatment with any approved or radiopharmaceuticals (for example, [177Lu]Lu-PSMA, [177Lu]-DOTA, or Radium- 223.)
  • Previous treatment with any external beam radiotherapy including hemi-body radiation within 6 weeks of randomization (within 2 weeks for radiotherapy of localized metastases).

    • Any prior PARP inhibitor or other systemic anticancer therapy administered for metastatic castration-resistant prostate cancer (mCRPC). Any other approved or investigational systemic therapy (including chemotherapy, immunotherapy, biologics, or monoclonal antibodies) is prohibited within 28 days or 5 half-lives (whichever is shorter) before randomization.

Note: Prior ARPI administered in the mHSPC setting or earlier may continue until C1D1.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
940 participants (estimated)

Study arms

  • Experimental
    Investigational Arm: AAA817+ARPI (enzalutamide or abiraterone)

    Participants will receive AAA817 infusion directly into a vein with ARPIs.

    Drug: AAA817 · Drug: ARPI

  • Experimental
    Investigational Arm: AAA817

    Participants will receive AAA817 infusion directly into a vein.

    Drug: AAA817

  • Active comparator
    Control arm: Investigator's choice of SoC (ARPI or chemotherapy or AAA617)

    Participants will receive standard treatment as decided by the trial doctor either as a taxane-based chemotherapy infusion directly into a vein or ARPI change either as capsules or tablets or AAA617 monotherapy infusion directly into a vein.

    Drug: ARPI · Drug: Standard of Care

Interventions

  • DrugAAA817

    AAA817 is being studied for treating PSMA positive mCRPC. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them. This treatment is also called a radioligand therapy.

    Also known as: [225Ac]Ac-PSMA-617

  • DrugARPI

    Androgen receptor pathway inhibitor (ARPI): An ARPI is approved for the treatment of prostate cancer. It works by blocking signals from male hormones, such as testosterone, that helps cancer cells grow. By blocking these signals, an ARPI slows down or stops the growth of prostate cancer cells. In this trial, participants will be given either enzalutamide or abiraterone.

    Also known as: Enzalutamide or Abiraterone

  • DrugStandard of Care

    Standard treatment includes approved treatment for mCRPC. In this trial, the trial doctor will decide which available treatment participants will receive. The trial doctor will select either an ARPI of enzalutamide or abiraterone, or a taxane based chemotherapy of docetaxel or cabazitaxel or \[177Lu\]Lu-PSMA-617 (AAA617).

    Also known as: ARPI enzalutamide, ARPI abiraterone, Taxane based chemotherapy of docetaxel, Taxane based chemotherapy of cabazitaxel, [177Lu]Lu-PSMA-617 (AAA617)

06

What researchers measure

Primary outcomes

  1. Radiographic Progression Free Survival (rPFS)

    Time to radiographic disease progression or death due to any cause.

    Time frame: From the date of randomization to the date of the first documented radiographic disease progression using conventional imaging, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

Secondary outcomes

  1. Overall Survival (OS) (Key Secondary Endpoint)

    Time to death due to any cause.

    Time frame: From the date of randomization to the date of death due to any cause, assessed up to approximately 40 months.

  2. Radiographic Progression Free Survival by by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST v1.1 (Key Secondary)

    Time to radiographic disease progression, using by blinded independent central review (BICR) using conventional imaging and Prostate Cancer Working Group 3 (PCWG3)-modified RECIST v1.1 criteria or death due to any cause.

    Time frame: From date of randomization to the date of the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

  3. Overall Survival in participants with PSMA-positive mCRPC treated with another ARPI. (Key Secondary)

    Time to death due to any cause.

    Time frame: From the date of randomization to the date of death due to any cause.

  4. rPFS in participants treated with AAA817

    rPFS time to the date of first documented radiographic disease progression or death due to any cause, whichever occurs first.

    Time frame: From the date of randomization to the date of the first documented radiographic disease progression, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

  5. Progression Free Survival (PFS)

    Time to first documented progression or death due to any cause.

    Time frame: From date of randomization to the first documented progression by investigator's assessment or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

  6. Progression Free Survival (PFS2)

    Time to first documented progression on next line of antineoplastic therapy or death from any cause.

    Time frame: From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to approximately 40.0 months.

  7. Overall Response Rate (ORR)

    The proportion of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR) in soft tissue.

    Time frame: From the date of randomization to the date of the first documented radiographic disease progression, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

  8. Disease Control Rate (DCR)

    The proportion of participants with BOR of confirmed CR, PR, stable disease (SD) or non-CR/non-progressive disease (PD) in soft tissue.

    Time frame: From the date of randomization to the date of the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

  9. Duration of Response (DoR)

    Time between the date of first documented response and the date of first documented radiographic progression or death due to any cause.

    Time frame: From the date of first documented response (CR or PR) for confirmed responders and the date of first documented radiographic progression in soft tissue or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

  10. Time to first radiographic soft tissue progression (TTSTP)

    Time to radiographic soft tissue progression.

    Time frame: From the date of randomization to the date of radiographic soft tissue progression or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

  11. Time to first symptomatic skeletal event (TTSSE)

    Time to date of first new symptomatic skeletal event of death due to any cause.

    Time frame: From the date of randomization to the date of the first documented radiographic disease progression, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

  12. Prostate specific antigen response (PSA50 and PSA90)

    The percentage of participants who achieved ≥ 50% and ≥ 90% decrease from baseline, respectively.

    Time frame: From the date of randomization to the date of safety follow up, assessed up to approximately 40.0 months.

  13. Time-concentration profiles and PK parameters of AAA817

    Time-concentration profiles and PK parameters of AAA817 (e.g. AUC, Cmax).

    Time frame: From Cycle 1 Day 1 up to approximately cycle 5 days 11 (each cycle is 8 weeks).

  14. Change from baseline on FACT-P Prostate Cancer Subscale (PCS)

    Change from baseline on FACT-P Prostate Cancer Subscale (PCS). FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment.

    Time frame: From randomization to the first occurrence of worsening on the score or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

  15. Time to worsening on the Worst Pain

    Time to worsening on the Worst Pain is defined as the time from randomization to the first occurrence of worsening on the Worst Pain item (BPI-SF) or death due to any cause, whichever occurs first.

    Time frame: From randomization to the first occurrence of worsening from baseline, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.

07

Study locations

106 of 106 sites recruiting
  • Urology Centers Of Alabama Pc
    Homewood, Alabama 35209, United States
    Recruiting
  • University of Arizona
    Tucson, Arizona 85724, United States
    Recruiting
    • Jeanette Cardenas · Contactserranoj@arizona.edu · 520-626-2340
    • Bital Savir-Baruch · Principal investigator
  • Univ Cali Irvine ALS Neuromuscular
    Orange, California 92868, United States
    Recruiting
    • Amanda Macaraeg · Contactmacaraeg@hs.uci.edu · 714-456-2332
    • Arash Rezazadeh Kalebasty · Principal investigator
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
    Recruiting
  • Sansum Clinic
    Santa Barbara, California 93105, United States
    Recruiting
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
    Recruiting
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
    Recruiting
  • Baptist Health South
    Miami, Florida 33173, United States
    Recruiting
  • AdventHealth
    Orlando, Florida 32804, United States
    Recruiting
  • University Cancer and Blood Center LLC
    Athens, Georgia 30607, United States
    Recruiting
  • Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
  • University of Illinois Cancer Center at Chicago
    Chicago, Illinois 60612, United States
    Recruiting
    • Ethan Gu · Contactegu3@uic.edu · 312-413-2746
    • Natalie Reizine · Principal investigator
  • Univ Of Iowa Hospitals And Clinics
    Iowa City, Iowa 52242, United States
    Recruiting
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
    Recruiting
    • Collin Bruey · Contactcbruey@kumc.edu
    • Xinglei Shen · Principal investigator
  • East Jefferson Hospital
    Metairie, Louisiana 70006, United States
    Recruiting
  • New England Cancer Specialists
    Scarborough, Maine 04074, United States
    Recruiting
    • Abigail Berard · Contactberara@newecs.org
    • Christian Anton Thomas · Principal investigator
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
    Recruiting
  • Beth Israel Deaconess Med Center
    Boston, Massachusetts 02215, United States
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
    Recruiting
    • Kimberlee Dobson · Contactdobsonk@karmanos.org · 313-576-9454
    • Nitin Vaishampayan · Principal investigator
  • Wash U School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68154, United States
    Recruiting
  • Astera Cancer Center
    East Brunswick, New Jersey 08816, United States
    Recruiting
  • New Jersey Urology LLC
    Voorhees Township, New Jersey 08043, United States
    Recruiting
  • New Mexico Oncology Hematology
    Albuquerque, New Mexico 87109, United States
    Recruiting
    • Kimberly Demos · Contactkimberlyd@nmohc.com · +1 505 822 3869#3867
    • Gregg Franklin · Principal investigator
  • Bassett Medical Center
    Cooperstown, New York 13326, United States
    Recruiting
  • Weill Cornell Medicine NY-Presb
    New York, New York 10021, United States
    Recruiting
  • University of Rochester Medical Ctr
    Rochester, New York 14642, United States
    Recruiting
  • Associated Med Professionals of NY
    Syracuse, New York 13210, United States
    Recruiting
  • Montefiore Medical Center
    The Bronx, New York 10461, United States
    Recruiting
  • Urology Group - Solaris Network
    Cincinnati, Ohio 45212, United States
    Recruiting
  • Central Ohio Urology Group
    Gahanna, Ohio 43230, United States
    Recruiting
  • MUSC Hollings Cancer Center
    Charleston, South Carolina 29425, United States
    Recruiting
    • Alex Jones · Contactjoalex@musc.edu
    • Kevin Becker · Principal investigator
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
  • Tennessee Oncology PLLC
    Chattanooga, Tennessee 37404, United States
    Recruiting
    • Mercedes Bruce · Contactmbruce@tnonc.com
    • Katy Beckermann · Principal investigator
  • Urology Austin
    Lakeway, Texas 78738, United States
    Recruiting
  • Urology San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
  • Woodlands Cancer Institute American Oncology Partners
    The Woodlands, Texas 77384, United States
    Recruiting
  • Swedish Medical Center
    Seattle, Washington 98122-4379, United States
    Recruiting
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
    Recruiting
  • West Virginia University Hospital
    Morgantown, West Virginia 26506, United States
    Recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Mariah Ziegler · Contactmziegler@mcw.edu · 414-805-5249
    • Deepak Kilari · Principal investigator
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
    Recruiting
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
    Recruiting
  • Novartis Investigative Site
    Malvern, Victoria 3144, Australia
    Recruiting
  • Novartis Investigative Site
    Murdoch, Western Australia 6150, Australia
    Recruiting
  • Novartis Investigative Site
    Adelaide, 5000, Australia
    Recruiting
  • Novartis Investigative Site
    São Paulo, São Paulo 01308-050, Brazil
    Recruiting
  • Novartis Investigative Site
    São Paulo, São Paulo 05652-000, Brazil
    Recruiting
  • Novartis Investigative Site
    Fuzhou, Fujian 350025, China
    Recruiting
  • Novartis Investigative Site
    Guangzhou, Guangdong 510120, China
    Recruiting
  • Novartis Investigative Site
    Guangzhou, Guangdong 510632, China
    Recruiting
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
    Recruiting
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
    Recruiting
  • Novartis Investigative Site
    Nanjing, Jiangsu 210006, China
    Recruiting
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
    Recruiting
  • Novartis Investigative Site
    Shenyang, Liaoning 110011, China
    Recruiting
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
    Recruiting
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310007, China
    Recruiting
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310022, China
    Recruiting
  • Novartis Investigative Site
    Beijing, 100034, China
    Recruiting
  • Novartis Investigative Site
    Beijing, 100036, China
    Recruiting
  • Novartis Investigative Site
    Guangzhou, 510060, China
    Recruiting
  • Novartis Investigative Site
    Shanghai, 200001, China
    Recruiting
  • Novartis Investigative Site
    Shanghai, 200025, China
    Recruiting
  • Novartis Investigative Site
    Shanghai, 200032, China
    Recruiting
  • Novartis Investigative Site
    Tianjin, 300300, China
    Recruiting
  • Novartis Investigative Site
    Tianjin, 300480, China
    Recruiting
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
    Recruiting
  • Novartis Investigative Site
    Gurgaon, Haryana 122002, India
    Recruiting
  • Novartis Investigative Site
    Bengaluru, Karnataka 560066, India
    Recruiting
  • Novartis Investigative Site
    Mumbai, Maharashtra 400012, India
    Recruiting
  • Novartis Investigative Site
    Nagoya, Aichi-ken 4668560, Japan
    Recruiting
  • Novartis Investigative Site
    Sapporo, Hokkaido 0608648, Japan
    Recruiting
  • Novartis Investigative Site
    Kobe, Hyōgo 6500017, Japan
    Recruiting
  • Novartis Investigative Site
    Kobe, Hyōgo 6500047, Japan
    Recruiting
  • Novartis Investigative Site
    Kamakura, Kanagawa 2478533, Japan
    Recruiting
  • Novartis Investigative Site
    Yokohama, Kanagawa 2360004, Japan
    Recruiting
  • Novartis Investigative Site
    Kumamoto, Kumamoto 8608556, Japan
    Recruiting
  • Novartis Investigative Site
    Chuo Ku, Tokyo 1040045, Japan
    Recruiting
  • Novartis Investigative Site
    Chiba, 2608717, Japan
    Recruiting
  • Novartis Investigative Site
    Fukuoka, 8110213, Japan
    Recruiting
  • Novartis Investigative Site
    Fukuoka, 8120033, Japan
    Recruiting
  • Novartis Investigative Site
    Fukuoka, 8128582, Japan
    Recruiting
  • Novartis Investigative Site
    Fukushima, 9601295, Japan
    Recruiting
  • Novartis Investigative Site
    Hiroshima, 7348551, Japan
    Recruiting
  • Novartis Investigative Site
    Kyoto, 6068507, Japan
    Recruiting
  • Novartis Investigative Site
    Mexico City, 03330, Mexico
    Recruiting
  • Novartis Investigative Site
    Singapore, 119074, Singapore
    Recruiting
  • Novartis Investigative Site
    Singapore, 168583, Singapore
    Recruiting
  • Novartis Investigative Site
    Singapore, 169608, Singapore
    Recruiting
  • Novartis Investigative Site
    Seoul, 01812, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 03080, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 03722, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 05505, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 06351, South Korea
    Recruiting
  • Novartis Investigative Site
    Seoul, 06591, South Korea
    Recruiting
  • Novartis Investigative Site
    Kaohsiung City, 833, Taiwan
    Recruiting
  • Novartis Investigative Site
    Taichung, 407219, Taiwan
    Recruiting
  • Novartis Investigative Site
    Tainan, 704302, Taiwan
    Recruiting

Showing the first 100 of 106 sites across 12 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Sep 2028, 38 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 38 months is close to that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Mar 3, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Sep 29, 2028
CompletionEst.
Nov 4, 2032
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added
Show 6 added (4 United States, 1 Japan, 1 Taiwan)
  • University of Arizona · Tucson, United States
  • New England Cancer Specialists · Scarborough, United States
  • Johns Hopkins Hospital · Baltimore, United States
  • West Virginia University Hospital · Morgantown, United States
  • Novartis Investigative Site · Kumamoto, Japan
  • Novartis Investigative Site · Tainan, Taiwan
Oct 15, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Central Ohio Urology Group · Gahanna, United StatesContact t•••@centralohiourology.com→S•••@centralohiourology.com
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    6 sites added
    Show 6 added (4 United States, 1 Japan, 1 Taiwan)
    • University of Arizona · Tucson, United States
    • New England Cancer Specialists · Scarborough, United States
    • Johns Hopkins Hospital · Baltimore, United States
    • West Virginia University Hospital · Morgantown, United States
    • Novartis Investigative Site · Kumamoto, Japan
    • Novartis Investigative Site · Tainan, Taiwan
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Central Ohio Urology Group · Gahanna, United StatesContact t•••@centralohiourology.com→S•••@centralohiourology.com
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06855277
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
Jul 1, 2025
Primary completion
Sep 29, 2028 (estimated)
Completion
Nov 4, 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion